Evidence map›Paper›PMID 41814945›Full record

ArticleAdvanced materials (Deerfield Beach, Fla.)2026

A Cryoprotectant-Compatible Nanoporous Platform for Stable and Scalable Delivery of Biopharmaceuticals.

Sian Lee, Seongchan Kim, Jooyeun Chong, Min-Gyeong Kim, Kayeong Lim, Nan-Ee Lee, Jahyun Koo, Jiheong Kang, Hyojin Lee

Abstract read
In one paragraph

Article in Advanced materials (Deerfield Beach, Fla.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sian LeeBiomaterial Research Center, Biomedical Research Division, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.
Seongchan KimBiomaterial Research Center, Biomedical Research Division, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.
Jooyeun ChongDepartment of Chemistry, Seoul National University, Seoul, Republic of Korea.
Min-Gyeong KimBiomedical Research Division, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.
Kayeong LimBiomedical Research Division, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.
Nan-Ee LeeBiomaterial Research Center, Biomedical Research Division, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.
Jahyun KooSchool of Biomedical Engineering, Korea University, Seoul, Republic of Korea.
Jiheong KangDepartment of Chemistry, Seoul National University, Seoul, Republic of Korea.
Hyojin LeeBiomaterial Research Center, Biomedical Research Division, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.ORCID 0000-0001-6367-9485

Funding

KIST Institutional ProgramKorea Health Industry Development Institute, Ministry of Health & Welfare, Republic of Korea RS-2023-KH135060Korea Health Industry Development Institute, Ministry of Health & Welfare, Republic of Korea RS-2024-00438476National Research Foundation of Korea RS-2022-NR072331National Research Foundation of Korea RS-2024-00403376
6 · The paper itself

Abstract

CRISPR-Cas9 ribonucleoproteins (RNPs) represent a promising class of biopharmaceuticals for treating genetic and complex diseases. However, their clinical translation is limited by instability during storage and delivery. Lyophilization offers a potential solution, though conventional approaches often compromise structural integrity and bioactivity under non-cryogenic conditions. Here, we have developed a nanostructured delivery platform, designated Nano Banker & Blowball (NB

Indexed as

Cryoprotective AgentsNanoporesAnimalsCRISPR-Cas SystemsFreeze DryingGene EditingHumansRibonucleoproteinsCryoprotective AgentsRibonucleoproteinsambient‐stable biopharmaceuticalsfreezed‐dried formulationgene editingnano banker & blowballscalable therapeutic platform

Identifiers

PMID41814945
PMCPMC13261376

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.